1. Home
  2. NUVL vs EXLS Comparison

NUVL vs EXLS Comparison

Compare NUVL & EXLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuvalent Inc.

NUVL

Nuvalent Inc.

HOLD

Current Price

$105.83

Market Cap

7.1B

Sector

Health Care

ML Signal

HOLD

Logo ExlService Holdings Inc.

EXLS

ExlService Holdings Inc.

HOLD

Current Price

$41.53

Market Cap

6.9B

ML Signal

HOLD

Company Overview

Basic Information
Metric
NUVL
EXLS
Founded
2017
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Business Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
7.1B
6.9B
IPO Year
2021
2006

Fundamental Metrics

Financial Performance
Metric
NUVL
EXLS
Price
$105.83
$41.53
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
15
5
Target Price
$135.00
$53.80
AVG Volume (30 Days)
548.0K
1.1M
Earning Date
02-26-2026
02-24-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
29.94
EPS
N/A
1.48
Revenue
N/A
$2,026,490,000.00
Revenue This Year
N/A
$15.32
Revenue Next Year
N/A
$11.37
P/E Ratio
N/A
$28.90
Revenue Growth
N/A
14.43
52 Week Low
$55.54
$37.30
52 Week High
$112.88
$52.43

Technical Indicators

Market Signals
Indicator
NUVL
EXLS
Relative Strength Index (RSI) 54.70 45.63
Support Level $97.43 $41.56
Resistance Level $108.65 $43.15
Average True Range (ATR) 4.95 0.81
MACD 0.48 -0.14
Stochastic Oscillator 82.96 35.35

Price Performance

Historical Comparison
NUVL
EXLS

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

About EXLS ExlService Holdings Inc.

ExlService Holdings Inc. is a business process management company that provides digital operations and analytical services to clients driving enterprise-scale business transformation initiatives that leverage the company's deep expertise in analytics, AI, ML, and cloud. The company offers business process outsourcing and automation services, and data-driven insights to customers across multiple industries. The company operates through four segments based on the products and services offered and markets served: Insurance, Healthcare, Emerging Business, and Analytics . The vast majority of the company's revenue is earned in the United States, and more than half of its revenue comes from Analytics segment.

Share on Social Networks: